/

MCRB

Seres Therapeutics, Inc.Closed

2.53−0.15 −5.60%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delay

Open

2.61

Prev close

2.68

Day range

2.512.61

52-week range

2.4229.98

Volume

44.02K0.65×

Mkt cap

25.41M

P/E ttm

—

Fwd P/E

-0.51

EPS ttm

-2.42

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−91.56%

Price Chart

Yahoo Finance · delayed

MCRBOct 12, 2026O 2.75H 2.78L 2.66C 2.68−0.03 (−1.11%)Vol 54.30K

SMA 504.34
SMA 2008.03

1Y change −85.98% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MCRB Seres Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.96%
1 month: −46.51%
3 months: −52.31%
6 months: −68.76%
Year to date: −81.99%
1 year: −85.98%

Valuation & ownership

Market cap: 25.41M
Enterprise value: 66.20M
P/E (ttm): —
Forward P/E: -0.51
PEG ratio: —
Price / book: 0.72
Price / sales (ttm): 13.50
EV / EBITDA: -0.89
EPS (ttm): -2.42
EPS (forward): -4.95
Beta (5y monthly): 0.31
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 10.04M
Float: 8.74M
Short % of float: 4.05%
Short ratio (days): 5.53
Held by insiders: 11.49%
Held by institutions: 22.93%
Avg volume (3m): 67.89K
50-day average: 4.34
200-day average: 8.03
52-week change: −85.98%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): oversold 21.7
vs 50-day SMA: −38.19%
vs 200-day SMA: −66.61%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 10.80%
Realised vol (20d, ann.): 60.6%
From 52-week high: −91.06%
From 52-week low: +10.74%

ANR

Analyst Consensus

2 analysts

Consensus

—

Mean target

17.00

+571.94% implied

Low 12.00Median 17.00High 22.00

Recommendation trend

Now2 / 0 / 0
1m ago2 / 0 / 0

Buy / hold / sell counts

DES

About Seres Therapeutics, Inc.

Yahoo Finance profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI microbiome and to improve GI mucosal barrier integrity through the inhibition of inflammatory bacteria and associated metabolites; and SER-147, a live biotherapeutic composition to prevent bacterial bloodstream and spontaneous bacterial peritonitis infections in patients with metabolic disease, including chronic liver disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 66
Headquarters: Cambridge, MA, United States
Website: serestherapeutics.com
Officers: Mr. Richard N. Kender B.S., M.B.A. Interim CEO & Executive Chair
Dr. Matthew R. Henn Ph.D. President & Chief Scientific Officer

SEAS

Seasonality · MCRB

2015–2026 · monthly returns

Strongest month Aug +60.01%Weakest month Oct −10.30%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	0.3	-41.4	1.5	-16.9	-0.7	7.8	-38.8	1.7	-31.8	-24.5			−83.0%
2025	1.7	-10.2	-7.8	-30.7	-27.3	57.6	28.4	32.8	1.6	-16.3	11.7	-17.3	−10.5%
2024	-19.3	0.9	-32.1	28.0	0.9	-27.6	85.1	-40.2	18.1	-13.3	19.5	-15.2	−40.6%
2023	-2.3	-7.7	12.3	-14.0	1.5	-3.2	0.4	-28.3	-31.0	-35.7	-32.0	34.6	−75.0%
2022	0.1	-4.1	-11.0	-33.6	-34.5	10.6	19.8	25.1	24.9	38.0	-26.6	-13.8	−32.8%
2021	-3.1	-19.8	8.1	1.1	1.4	13.0	-70.2	-9.7	8.6	-12.6	77.0	-22.6	−66.0%
2020	-5.5	-3.7	13.7	3.1	49.2	-13.3	-21.4	608.3	6.9	-1.5	-1.0	-11.3	+610.1%
2019	36.3	-0.5	12.1	-4.8	-47.9	-5.6	-15.2	47.6	-0.5	-12.7	12.9	-12.7	−23.7%
2018	-0.4	-5.9	-22.7	4.5	5.0	6.8	-12.0	16.0	-13.6	-9.5	21.5	-45.9	−55.4%
2017	-0.1	-2.1	16.4	-12.8	-7.2	23.9	19.7	3.7	14.3	-37.4	4.6	-3.4	+2.4%
2016	-23.3	-14.2	14.9	11.1	3.1	-4.5	-62.3	-4.3	17.4	-12.2	-7.4	-0.9	−71.8%
2015							-8.8	9.2	-28.3	0.0	20.9	-2.1	−15.4%

INSD

Insider Activity · MCRB

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

2.8K shares

Sells, 6 months

964 shares

Net shares

+1.8K

Net change in insider shares

+0.20%

Date	Insider	Transaction	Shares	Value
Aug 16, 2026	Shaff Eric DDirector	Sale at price 4.55 per share.	263	$1.20K
Aug 16, 2026	Henn Matthew RPresident	Sale at price 4.55 per share.	81	$369
Aug 16, 2026	Brady KellyChief Operating Officer	Sale at price 4.55 per share.	64	$291
Aug 16, 2026	Desrosier Thomas JOfficer	Sale at price 4.55 per share.	82	$373
Aug 13, 2026	Brady KellyChief Operating Officer	—	181	—
Aug 13, 2026	Desrosier Thomas JOfficer	—	245	—
Aug 13, 2026	Shaff Eric DDirector	—	722	—
Aug 13, 2026	Henn Matthew RPresident	—	238	—
May 17, 2026	Shaff Eric DDirector	Sale at price 7.53 per share.	259	$1.95K
May 17, 2026	Henn Matthew ROfficer	Sale at price 7.53 per share.	77	$580
May 17, 2026	Brady KellyChief Operating Officer	Sale at price 7.53 per share.	59	$444
May 17, 2026	Desrosier Thomas JOfficer	Sale at price 7.53 per share.	79	$595
May 14, 2026	Brady KellyChief Operating Officer	—	180	—
May 14, 2026	Desrosier Thomas JOfficer	—	244	—
May 14, 2026	Shaff Eric DDirector	—	722	—
May 14, 2026	Henn Matthew ROfficer	—	238	—
Feb 12, 2026	Shaff Eric DDirector	Sale at price 8.47 per share.	259	$2.19K
Feb 12, 2026	Henn Matthew ROfficer	Sale at price 8.47 per share.	89	$754
Feb 12, 2026	Young Teresa L.Officer	Sale at price 8.47 per share.	75	$635
Feb 12, 2026	Desrosier Thomas JChief Executive Officer	Sale at price 8.47 per share.	78	$661

MCRB

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MCRB

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Seres Therapeutics, Inc.

Seasonality · MCRB

Insider Activity · MCRB

Congress Trades · MCRB

Investors Holding MCRB

Investors Holding MCRB

Congress Trades · MCRB

Insider Activity · MCRB

Seasonality · MCRB

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Seres Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News